National Institute of Advanced Industrial Science and Technology

Tokyo Medical University

The University of Toyama

Public University Corporation Nagoya City University

National Center for Global Health and Medicine

Science & Technology Corporation

Glycobiomarker Leading Innovation Co., Ltd.

National Institute of Advanced Industrial

Hiroyuki Kaji

Hisashi Narimatsu

Atsushi Kuno

Akira Togayachi

Takashi Sato

Yasunori Chiba

Yuzuru Ikehara

Takashi Ohkura

Masayuki Noguchi

Masaharu Nomura

Hiroaki Tateno

Masashi Mizokami

Maki Sogabe

Masanori Goto

Hideki Matsuzaki

Yoshitoshi Hirao

Jun Iwaki

Minako Abe

Jun Hirabayashi

Yasuhito Tanaka

Toshihide Shikanai

Makoto Ochou

Kiyohiko Angata

Hiroki Shimizu

Takanori Wagatsuma

Masaaki Korenaga

Kazuto Tajiri

Takashi Angata

Tatsuhiko Ozawa

An examination system that recognizes a glycosylated antigen in Dane particles of hepatitis B virus (HBV) and a neutralizing antibody that recognizes the glycosylated antigen and that exhibits an infection-inhibiting activity. It was elucidated that Dane particles are associated with specific glycan structures, and this enabled the construction of a new detection system for infectious, i.e., nucleic acid-containing, hepatitis B virus particles and the provision of a neutralizing antibody that recognizes a glycosylated antigen and that exhibits an infection-inhibiting activity.

Method for efficiently inducing antibody, antibody and detection system for hepatitis virus

An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.

Lung cancer differential marker

Amonomeric lectin polypeptide is provided. Themonomeric lectin polypeptide includes any one of the amino acid sequences selected from the group consisting of: (1) the amino acid sequence represented by SEQ ID NO: 2; (2) the amino acid sequence defined in (1) above, except that one to 20 amino acids at positions other than Cys272 position is/are deleted, substituted, inserted, or added; and (3) the amino acid sequence defined in (1) or (2) above, further having an N-terminus deletion of one to 30 amino acids, in which Cys272 is alkylated, and the polypeptide is capable of specifically binding to a GalNAc terminal sugar chain.

Modified lectin derived from Wisteria floribunda

The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.

Glycan markers as measure of disease state of hepatic diseases

[Problem] The purpose of the present invention is to stably supply high-quality and highly uniformagglutinin (WFA) that recognizes biologically important sugar-chain markers, to elucidate the sugar-chain recognition activity in detail, and to furthermore increase the specificity of the sugar-chain recognition activity. [Solution] The present invention involves the development of a technique for cloning genes for codingagglutinin (WFA) and producing recombinant WFA having the same sugar-chain recognition activity as natural WFA from transformed bacteria. Natural WFA is reduced to thereby manufacture a reduced WFA monomer for specifically recognizing terminal GalNAc residue. A recombinant monomer WFA for recognizing LDN (GalNAc&#x3b2;1, 4GlcNAc) sugar chain, which is important as a diagnostic marker among sugar chains having a terminal GalNAc residue, is manufactured by introducing cysteine mutation to recombinant WFA or by C-terminal-side amino acid deletion.

Growing community of inventors

Tsukuba, Japan

Hiroyuki Kaji